September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
An International Survey of Classification and Treatment Choices for Group D Retinoblastoma Eyes
Author Affiliations & Notes
  • Christina Scelfo
    Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • Jasmine H Francis
    Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • Thomas Lee Jenkins
    WillsEye Hospital, Philadelphia, Pennsylvania, United States
  • Brian P Marr
    Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • David H Abramson
    Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • Footnotes
    Commercial Relationships   Christina Scelfo, None; Jasmine Francis, None; Thomas Jenkins, None; Brian Marr, None; David Abramson, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3676. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Christina Scelfo, Jasmine H Francis, Thomas Lee Jenkins, Brian P Marr, David H Abramson; An International Survey of Classification and Treatment Choices for Group D Retinoblastoma Eyes. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3676.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The purpose of this international survey of Group D retinoblastoma was to: 1) determine which International Classification of Retinoblastoma (ICRB), scheme was used by retinoblastoma centers worldwide, 2) determine the percentage of D eyes primarily enucleated in each center, 3) correlate initial treatment options and patient outcome and 4) report on patient survival worldwide.

Methods : An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about treatment patterns and classification schemes used between 2008-2012.

Results : The survey was completed by 29.5% of centers dispersed through Asia, Africa, Middle East, Europe, US, and Latin America. 1807 D eyes were diagnosed. Regarding ICRB system, 27.6% of centers used the Children’s Hospital of Los Angeles version, 34.5% used the Children's Oncology Group version, 24.1% used the Philadelphia version, and 13.8% were unsure which version they used. The rate for primary enucleation varied between 0 and 100%. By continent, the primary enucleation rates were: South America, 57.7%; Asia, 40.4%; Europe, 36.0%; US, 8.4%; and Middle East, 8.3% as shown in Figure 1. 26% of centers did not primarily enucleate any eye and 26% of centers primarily enucleated greater than 50% of eyes. Patient survival ranged from 0% to 100% following primary enucleation and 31.2% to 100% following globe-salvaging strategies, with summative data demonstrated in Figure 2.

Conclusions : The above results suggest there is no consensus on which ICRB version is used to classify group D eyes worldwide. Regarding treatment, the primary enucleation rate varied greatly across centers, particularly by continent. Systemic chemoreduction, however, was the most frequently used initial treatment for group D eyes treated between 2008 and 2012. Survival was greatest in patients treated with either bridging chemotherapy plus intra-arterial chemotherapy followed by intra-arterial chemotherapy alone.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Figure 1. AFR=Africa, EUR=Europe, ME=Middle East, LA=Latin America.

Figure 1. AFR=Africa, EUR=Europe, ME=Middle East, LA=Latin America.

 

Figure 2. *Based on mortality from metastatic disease, complications of treatment, or secondary cancer.

Figure 2. *Based on mortality from metastatic disease, complications of treatment, or secondary cancer.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×